Aldosteronism Clinical Trial
Official title:
Postoperative Cardiovascular Index Change of Primary Aldosteronism
Primary aldosteronism (PA), characterized by an inappropriate production of aldosterone, is far more common than is usually perceived. The overall prevalence of PA is 11.2% of the newly diagnosed hypertensive patients and 4.8% was curable aldosterone producing adenoma (APA), and adrenalectomy is considered the treatment of choice for APA. The potential curability and prevention of excess cardiovascular damage and events also underscores the need to develop accurate strategies for the timely diagnosis of APA.This study aimed to determine the effects of endothelium function change ( PWV, progenitor cell,..) before and post-adrenalectomy or taking spironolactone in patients with aldosteronism. Autonomous elevated aldosterone will increase the glomerular filtration rate and renal damage in patients with primary aldosteronism (PA). But clinical evidence of the role of endothelium function on post-adrenalectomy or taking spirolactone is still limited.
Aldosterone has rapid nongenomic effects in the human vasculature. Aldosterone has been
claimed to lead to endothelial dysfunction, a condition related to development of
cardiovascular disorders and to poor prognosis. However, studies of aldosterone effects on
endothelial function led to discrepant findings, which may be related, at least in part, to
inhomogeneity of the populations studied. Thus, studies in healthy subjects showed no
detrimental effects of aldosterone on endothelial function and no positive effect of
aldosterone inhibition, whereas populations with established cardiovascular diseases showed
negative effects of aldosterone and positive effects of spironolactone therapy. Still, other
factors may be of importance as effects of aldosterone on endothelial function are not
homogenous even in a healthy population. Dosages of aldosterone, concomitant drug use, as
well as the vascular bed investigated may influence the effects observed.
Furthermore, little is known about chronic endothelial effects of aldosterone that could
indicate a primary and direct role of aldosterone in development of cardiovascular diseases.
In patients with hyperaldosteronism diminished flow-mediated dilation was found, indicating
impaired endothelial function compared with hypertensive patients without elevated
aldosterone. However, it is not known whether these results represent endothelial
dysfunction as the result of a direct aldosterone effect on the vasculature or a secondary
effect attributable to more substantial hypertension.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04890444 -
China Adrenal Disease Registry
|
||
Completed |
NCT01267747 -
Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation
|
||
Recruiting |
NCT06090617 -
Water and Electrolytes Content in HYpertension (WHYSKI) in the SKIn
|
||
Recruiting |
NCT05232162 -
Establishment of Aldosterone and Renin Reference Range
|